The Recall Desk

Manufacturer

Pacira Pharmaceuticals, Inc.

4 recalls in our database name Pacira Pharmaceuticals, Inc. as the manufacturing or recalling firm.

What the numbers show

Total
4
Critical
0
Severe
1
Most recent
2024-07-03

Of the 4 recalls from Pacira Pharmaceuticals, Inc. we have scored against our rubric, 0 (0%) are Critical — deaths or serious injuries reported, or the agency’s own highest classification — and 1 (25%) are Severe.

About this listing

The manufacturer string comes from the agency’s own source notice — for FDA recalls, the “recalling firm” field; for NHTSA recalls, the vehicle manufacturer; for CPSC recalls, the firm-of-record on the joint press release. A single corporate family can appear under multiple manufacturer strings as agency notices aren’t standardized on a canonical name. If you don’t see recalls you expect, try a parent-company search or a broader full-text search.

Severity scores below are computed from the agency’s classification and the recall text, never from manufacturer behaviour or history. Many manufacturers issue routine corrective actions (software updates, labelling corrections) that are correctly scored low — having recalls on this list isn’t inherently a quality signal.

1–4 of 4

  • HighFDA (Drugs)·D-0546-2024·2024-06-19

    Zilretta Injectable Drug Recalled for Failed Stability Specifications

    Pacira Pharmaceuticals is recalling 43,768 kits of Zilretta injectable suspension due to failed stability specifications at 2–8°C storage for 12 months followed by 25°C for 6 weeks. No illnesses or injuries have been reported.

    Product
    ZILRETTA — ZILRETTA (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION)
    Category
    Drug
    Distribution
    Distributed nationwide
  • ModerateFDA (Drugs)·D-0621-2020·2019-12-11

    Pacira Recalls Sub-Potent Exparel Bupivacaine Injectable Vials

    Pacira Pharmaceuticals is recalling 910 vials of Exparel (Bupivacaine) because the drug was found to be sub-potent and out of specification.

    Product
    EXPAREL — EXPAREL (BUPIVACAINE)
    Category
    Drug
    Distribution
    Distributed nationwide
  • SevereFDA (Drugs)·D-168-2013·2013-03-06

    Pacira Recalls Subpotent EXPAREL Bupivacaine Injectable Vials

    Pacira Pharmaceuticals is recalling 324 vials of EXPAREL (bupivacaine liposome injectable suspension) because the product is subpotent.

    Product
    EXPAREL (bupivacaine liposome injectable suspension), 1.3%, 266 mg/20 mL (13.3 mg/mL) single use vials, INVESTIGATIONAL USE. For Infiltration Only. Not for any other route of administration. Manufactured by Paelra Pharmaceuticals. Inc., San Diego, California, USA
    Category
    Drug
    Distribution
    Distributed nationwide

About this company

Community-sourced company facts from Wikidata, not from any recall agency. This is background on the corporate entity — it says nothing about the recall(s) listed on this page, which come from the agency source notice above.

Pacira Pharmaceuticals, Inc.

specialty pharmaceutical company

Country
United States
Founded
2006

Official website

Source: Wikidata (Q21874175), licensed CC0. Wikidata is community-edited and may not reflect the current corporate structure.